• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by AstraZeneca

    < Previous 1 2 3 4 5 6 7 Next >
    AstraZeneca Announces Winners of Fourth Annual Cancer Community Awards
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    AstraZeneca Partners with Jeff Bridges, Kumail Nanjiani, and Emily V. Gordon to Educate the Immunocompromised Community about Added Protection Against COVID-19
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    IMFINZI® (durvalumab) plus chemotherapy further improved overall survival benefit in advanced biliary tract cancer in the TOPAZ-1 Phase III trial, reducing the risk of death by 24% in additional follow-up
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    ENHERTU® (fam-trastuzumab deruxtecan-nxki) Continues to Demonstrate Clinically Meaningful Tumor Response in Patients with HER2-mutant Metastatic Non-small Cell Lung Cancer
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    IMFINZI® (durvalumab) and tremelimumab with chemotherapy demonstrated sustained survival benefit in metastatic non-small cell lung cancer, nearly doubling the number of patients alive after three years vs. chemotherapy
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    TAGRISSO® (osimertinib) demonstrated 5.5-year median disease-free survival in the adjuvant treatment of patients with EGFR-mutated lung cancer
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    LYNPARZA® (olaparib) in Combination with Bevacizumab, and as a Monotherapy, Demonstrates Clinically Meaningful Survival Benefit in 1st-Line Advanced Ovarian Cancer Across Two Phase III Trials
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    IMFINZI® (durvalumab) Plus Chemotherapy Approved in the US as the First Immunotherapy Regimen for Patients with Advanced Biliary Tract Cancer
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    New data show FARXIGA significantly lowers the risk of cardiovascular death in patients with heart failure
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    FARXIGA significantly reduced the risk of cardiovascular death or worsening of heart failure in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    AstraZeneca aims to transform cancer outcomes with new data across industry-leading portfolio at ESMO 2022
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    LYNPARZA® (olaparib) in combination with abiraterone granted Priority Review in the US for patients with metastatic castration-resistant prostate cancer
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    TAGRISSO® plus savolitinib demonstrated 49% objective response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    CALQUENCE® (acalabrutinib) tablet formulation approved in the US across current indications
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low metastatic breast cancer
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    AstraZeneca Shares Data at EASL and ESMO World GI for IMFINZI® (durvalumab) Combinations in Patients With Liver and Biliary Tract Cancers
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    PROpel Phase III Trial Positive Results of LYNPARZA® (olaparib) Plus Abiraterone in 1st-line Metastatic Castration-resistant Prostate Cancer Published in New England Journal of Medicine Evidence
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    Eplontersen Met Co-Primary and Secondary Endpoints in Interim Analysis of the NEURO-TTRansform Phase III Trial for Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (ATTRv-PN)
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    ENHERTU® (fam-trastuzumab deruxtecan-nxki) Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2-Low Metastatic Breast Cancer with HR-Positive and HR-Negative Disease
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    CALQUENCE Plus Obinutuzumab Demonstrated Sustained Survival Benefit in 1st-line Chronic Lymphocytic Leukemia with 90% of Patients Surviving Five Years in ELEVATE-TN Trial
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    First Patients Dosed in IRIS Phase III Trial Evaluating Anifrolumab in Lupus Nephritis
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    AstraZeneca aims to transform cancer care with practice-changing data at ASCO 2022
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    PT027, a Novel Fixed-Dose Combination of Albuterol and Budesonide, Used as an As-Needed Rescue Medicine, Significantly Reduced the Risk of a Severe Exacerbation Compared to Albuterol by 27% in Patients With Asthma
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    FARXIGA met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    ULTOMIRIS® (ravulizumab-cwvz) Met Primary Endpoint in CHAMPION-NMOSD Phase III Trial in Adults with Neuromyelitis Optica Spectrum Disorder
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    Imfinzi Plus Chemotherapy Granted Priority Review in the US for Patients With Locally Advanced or Metastatic Biliary Tract Cancer Based on TOPAZ-1 Phase III Trial
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    ULTOMIRIS® (ravulizumab-cwvz) Approved in the US for Adults with Generalized Myasthenia Gravis
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    < Previous 1 2 3 4 5 6 7 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.